In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of ...
Tags: Identify New Drug Candidates, unparalleled selectivity, cell permeable
CEL-SCI Corporation has received approval from the Medicines and Medical Device Agency of Serbia to begin enrollment of subjects in its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment ...
US-based Advanced Proteome Therapeutics has announced the achievement of an important milestone in its Cprogram with its collaborators by demonstrating that the first of a series of the company's site-specifically labeled protein conjugates ...
Tags: therapeutics, anti-cancer, proteome, Cprogram
Daiichi Sankyo Company has decided to expand its collaborative drug discovery program with universities and research institutions based in Japan, Take a New challenge for Drug diScovery (TaNeDS) Global Program, to Germany, Switzerland and ...
Tags: Daiichi Sankyo, Medicine
Boston Biomedical has relocated its headquarters to Cambridge, Massachusetts with the opening of a new 64,000ft2 facility, in a bid to advance its efforts in discovering next generation of targeted cancer therapeutics. Commenting on the ...
Tags: Boston, Cambridge, Biomedical
Ablynx has signed a collaborative agreement with Spirogen to evaluate the potential of a novel anti-cancer drug conjugate. As part of the deal, both the firms will evaluate anti-cancer drug conjugate by using Spirogen's proprietary ...
Tags: Ablynx inks, anti cancer drug, drug
Scientists funded by Cancer Research UK are using virtual experiments in a bid to find the best methods for drug discovery. The findings have been published in the Nature Reviews Drug Discovery journal, with the work combining a unique ...
Tags: Cancer Research UK, virtual experiments, drug discovery, online database
ApoCell will present the study abstracts of its circulating tumor cells (CTC) recovery technology at the Molecular Targets and Cancer Therapeutics Conference, which will be held in Dublin, Ireland from 6-9 November 2012. Using a ...
Tags: CTC Recovery Technology, medical study, medical technology
Amorfix Life Sciences and CNJ Holdings have signed an agreement to identify and develop therapeutic antibodies targeting disease specific epitopes (DSEs). The collaboration will make use of Amorfix's ProMIS discovery technology and the ...
Tags: Amorfix Life Sciences, CNJ Holdings, agreement, disease specific epitopes
Cancer Therapeutics CRC has selected Dotmatics' enterprise platform for data querying and analysis across its multiple research sites in Australia. CRC implemented Browser, Dotmatics' enterprise query platform, and Vortex, a premium data ...
Tags: Cancer Therapeutics CRC, Dotmatics'enterprise platform
TNI BioTech and Hubei Qianjiang Pharmaceutical have entered into a partnership to develop new cancer therapeutics. The cancer drugs will be based on TNI BioTech's patents covering Methionine Enkephalin. TNI BioTech will carry out ...
Tags: Hubei Qianjiang Pharmaceutical, cancer drugs, methionine enkephalin
Cancer Therapeutics has announced the validation and performance of CTx-294886 in combination with Avastin in a preclinical model of basal breast cancer. The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) ...
Tags: cancer therapeutics, CTx-294886, basal breast cancer, FAK inhibitor
Advanced Cancer Therapeutics (ACT) has received Phase I small business innovative research (SBIR) grant of $158,000 from the National Cancer Institute of the National Institutes of Health (NIH) to support the development of an anti cancer ...
Tags: ACT, SBIR Grant, anti cancer drug, Anticancer Drug
VentiRx Pharmaceuticals has formed a world-wide collaboration with Celgene Corporation to develop VTX-2337, a highly potent and selective TLR8 agonist for cancer treatment. As part of the agreement, Celgene will fund $35m as upfront ...
Rosetta Genomics has won a European patent covering the use of miR-34a in the preparation of pharmaceuticals used to treat p53-negative cancers. The patent covers a core element of Rosetta's microRNA technology in the development of ...
Tags: European patent, p53-negative cancer, miR-34a, clinical technology